Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Chafika Mazouni"'
Autor:
Véronique Scott, Alexander Valent, Ivan Bièche, Suzette Delaloge, Mohamed Amine Bayar, I. Bouakka, Fabrice Andre, Corinne Balleyguier, Audrey Rapinat, Stefan Michiels, David Gentien, V. Leroux-Kozal, Magali Lacroix-Triki, Chafika Mazouni, Virginie Marty, Bianca Cheaib, Monica Arnedos, Benjamin Sarfati, Julien Adam
Publikováno v:
Annals of Oncology. 29:1755-1762
The cyclin-dependent kinase 4 (CDK4)/6 inhibitor Palbociclib is a new standard treatment in hormone-receptor positive breast cancer patients. No predictive biomarkers have been identified and no pharmacodynamics has properly been described so far.Pat
Autor:
Muriel Abbaci, Stefan Michiels, F. de leeuw, M. Karim, Corinne Laplace-Builhé, M-C Mathieu, Angelica Conversano, Chafika Mazouni
Publikováno v:
Annals of Oncology. 32:S56
Autor:
Pierre-Jean Lamy, Anne-Gaëlle Le Corroller, Diana Kassab-Chahmi, Laetitia Verdoni, Julia Bonastre, Elisabeth Luporsi, Valérie Mazeau-Woynar, Frédéric Fina, Chafika Mazouni, Patricia de Cremoux, Jérôme Barrière, J. P. Peyrat, Jean-Pierre Bellocq, Pierre-Marie Martin, Gilles Romieu, Jérôme Chetritt, Anne-Sophie Gauchez
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, 2015, 102 (9), pp.719-729. ⟨10.1016/j.bulcan.2015.05.003⟩
Bulletin du Cancer, John Libbey Eurotext, 2015, 102 (9), pp.719-729. ⟨10.1016/j.bulcan.2015.05.003⟩
Annales de Pathologie
Annales de Pathologie, 2014, 34 (5), pp.349-351. ⟨10.1016/j.annpat.2014.04.010⟩
Bulletin du Cancer, 2015, 102 (9), pp.719-729. ⟨10.1016/j.bulcan.2015.05.003⟩
Bulletin du Cancer, John Libbey Eurotext, 2015, 102 (9), pp.719-729. ⟨10.1016/j.bulcan.2015.05.003⟩
Annales de Pathologie
Annales de Pathologie, 2014, 34 (5), pp.349-351. ⟨10.1016/j.annpat.2014.04.010⟩
CONTEXT AND AIMS:Breast cancer prognosis and predictive biomarkers development would allow sparing some patients from chemotherapy or identifying patients for whom chemotherapy would be indicated. In this context, in 2009, the French National Cancer
Autor:
Marie Bannier, Fabien Reyal, Charles Coutant, J-M Classe, Armando J. Martínez, A. Berthelot, Emile Daraï, A. De Nonneville, Monique Cohen, M.-P. Chauvet, P. Guimbergues, R. Villet, G. Houvenaeghel, A. Gonçalves, Chafika Mazouni, C. Tunon de Lara, Nicolas Chopin, Roman Rouzier, A.-S. Azuar
Publikováno v:
Annals of Oncology. 30:v64
Background Elderly breast cancer (BC) patients have been underrepresented in clinical trials whereas ∼60% of deaths from BC occur in women aged 65 years and older. The management of elderly women with early BC requires careful evaluation of risks a
Autor:
Fabrice Andre, M.G. Erlander, Catherine A. Schnabel, Suzette Delaloge, J. Passeron, N.C. Kesty, Chafika Mazouni, Véronique Scott, Monica Arnedos, Y. Zhang, M.C. Mathieu
Publikováno v:
Annals of Oncology. 23:2046-2052
Background The aim of neoadjuvant chemotherapy is to increase the likelihood of successful breast conservation surgery (BCS). Accurate identification of BCS candidates is a diagnostic challenge. Breast Cancer Index (BCI) predicts recurrence risk in e
Autor:
Céline Bourgier, Manel Barhi, Abir Al Ghuzlan, Chafika Mazouni, Hugo Marsiglia, Ismael Ghorbel, Suzette Delaloge, S. Heymann, Corinne Balleyguier
Publikováno v:
Radiotherapy and Oncology. 103:151-154
Even though tumor progression under neoadjuvant chemotherapy is uncommon, its locoregional management remains absolutely unclear. What is the best time for radical surgery or radiotherapy? "Rescue" chemo-radiotherapy could be a suitable radiosensitiz
Autor:
Maryam Mehrpour, Salem Chouaib, J. Grassi, N. Morel, Franck Meslin, M-C Mathieu, Rosa Conforti, Suzette Delaloge, Fabrice Andre, G. Tomasic, Françoise Drusch, M. Yacoub, Chafika Mazouni, Jean-Christophe Sabourin
Publikováno v:
Annals of Oncology. 18:1793-1798
Background: Prion protein (PrPc) has been previously reported to be associated with resistance to proapoptotic stimuli. We evaluated whether the expression of PrPc was associated with the resistance to adjuvant chemotherapy in patients with estrogen
Autor:
Aman U. Buzdar, William Fraser Symmans, Thomas A. Buchholz, Lajos Pusztai, Gabriel N. Hortobagyi, S. W. Kau, Henry Mark Kuerer, Karen O. Anderson, A. M. Gonzalez-Angulo, Kenneth R. Hess, Debra Frye, Fabrice Andre, Chafika Mazouni
Publikováno v:
Annals of Oncology. 18:874-880
Background: We examined if inclusion of a taxane and more prolonged preoperative chemotherapy improves pathologic complete response (pCR) rate in estrogen receptor (ER)-positive breast cancer compared with three to four courses of 5-fluorouracil, dox
Autor:
Pierre-Marie Martin, Chafika Mazouni, Pascal Bonnier, Frédéric Fina, L’houcine Ouafik, Sylvie Romain
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Clinical Oncology, Springer Verlag, 2015, 141 (6), pp.1083-1088. ⟨10.1007/s00432-014-1889-7⟩
Journal of Cancer Research and Clinical Oncology, 2015, 141 (6), pp.1083-1088. ⟨10.1007/s00432-014-1889-7⟩
Journal of Cancer Research and Clinical Oncology, Springer Verlag, 2015, 141 (6), pp.1083-1088. ⟨10.1007/s00432-014-1889-7⟩
Journal of Cancer Research and Clinical Oncology, 2015, 141 (6), pp.1083-1088. ⟨10.1007/s00432-014-1889-7⟩
International audience; PURPOSE: To develop a prognostic nomogram to predict freedom from recurrence for patients treated with adjuvant hormonal therapy (HT) for localised breast cancer (BC).METHODS: We performed a retrospective analysis of 142 patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e36fec7da5a7067bc64441c91f26afd
https://hal-amu.archives-ouvertes.fr/hal-01480127
https://hal-amu.archives-ouvertes.fr/hal-01480127
Publikováno v:
Medical oncology (Northwood, London, England). 31(3)
BRCA2 mutation carriers typically develop luminal B breast cancers. Data on the effectiveness of neoadjuvant chemotherapy in these patients are limited because of small patient numbers and lack of prospective studies. We used our 15-year genetic clin